Sanofi

Non-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 million people in 2018 as per WHO, with lung cancer being the most commonly diagnosed one and accounting for the highest number of deaths (1.76...

The dream of the UAE government to place its capital city among the best cities in the world has led to the introduction of ‘Dubai plan 2021’, focused on transforming into a smart city through an investment of more than USD 7 Billion. Dubai’s smart city strategy includes over 100 initiatives, which aims at fosterin...

The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC)  The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized wit...

Gaucher Disease Market is anticipated to enhance in the forecast period owing to a strong Gaucher disease pipeline. According to the National Organization of Rare Diseases, Gaucher disease is a rare, inherited, metabolic disorder, which is characterized by an accumulation of harmful fats, chiefly the glycolipid ...

Merck is set to complete the already planned purchase of the ArQule for USD 2.7 Billion. Under the terms of the agreement, Merck will pay USD 20 for each share in cash for a total amount of USD 2.7 Billion. ArQule is a biopharmaceutical, which is focused on kinase inhibitor discovery, finding cures for cancer p...

Cumberland Pharmaceuticals has recently received approval from the US FDA for its RediTrex injection for the treatment of rheumatoid arthritis. Cumberland pharmaceuticals pharma company focusing on acquiring and commercializing prescription products has gained access to the injection from Nordic Group two years...

Sanofi’s Toujeo has received FDA recommendation for its expanded use in Type 1 Diabetes. Toujeo is an insulin glargine injection to control the highs and lows of blood sugar in the body. Indicated to be used in adults and paediatric patients of age six and older. Earlier, the injection was considered suitab...

EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has issued guidelines regarding the funding of Libtayo (cemiplima). Libtayo, co-developed by Sanofi and Regeneron, was granted...

Sanifit raises USD 80.9 M to advance Calciphylaxis Pipeline Sanifit, a clinical-stage biopharmaceutical company, has raised USD 80.9 million ( €72.2 million ) in total private fundraising. The financing mainly consisted led by Spain’s Caixa Capital Risc, along with many new investors, including Columbus Venture ...

The European Commission approved Zynquista (sotagliflozin) as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents the SGLT-1 and SGLT-2 proteins that impact how the intestines and kidneys absorb and glucose that will result in better diabetes control. Sanofi is collaborating ...